Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 2Phase 3 1Phase 2/3 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1

Conditions

Sarcoma 1Neoplasm Metastasis 1Hematologic Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1

Interventions

pembrolizumab 409Cyclophosphamide 398Carboplatin 307Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 209Bevacizumab 207fludarabine 195Docetaxel 186Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 121Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Drug Combinations × Clear all
NCT07220616 2026-05-08

A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies

Daiichi Sankyo

Phase 1/2 Recruiting
420 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT04138381 2023-03-27

SeliGIST

Grupo Espanol de Investigacion en Sarcomas

Phase 1/2 Unknown
30 enrolled
Sarcoma

Neoplasm Metastasis, Sarcoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡